Biocon Foundation is also expanding its reach with this first initiative in Channapatna region
AHLL will become a 100% subsidiary of AHEL with 99.42% held by AHEL and balance in the ESOP pool
Both will develop a non-viral manufacturing workflow designed to eliminate key bottlenecks and accelerate the delivery of lifesaving engineered cell therapies to patients
The portfolio acquired includes Stugeron brand as well as its leading local brands STUGERON FORTE and STUGERON PLUS across 18 markets in the APAC and EMEA regions
Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines
The cGMP-4 facility will further strengthen the company's ability to serve global partners
The Ma’anshan site approval covers pastilles, oral liquids, and powders
Subscribe To Our Newsletter & Stay Updated